Advertisement
Canada markets open in 1 hour 58 minutes
  • S&P/TSX

    22,265.05
    -108.35 (-0.48%)
     
  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     
  • DOW

    38,852.86
    -216.74 (-0.55%)
     
  • CAD/USD

    0.7314
    -0.0023 (-0.31%)
     
  • CRUDE OIL

    80.48
    +0.65 (+0.81%)
     
  • Bitcoin CAD

    92,729.37
    -864.02 (-0.92%)
     
  • CMC Crypto 200

    1,462.39
    -22.31 (-1.50%)
     
  • GOLD FUTURES

    2,344.10
    -12.40 (-0.53%)
     
  • RUSSELL 2000

    2,066.85
    -2.82 (-0.14%)
     
  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     
  • NASDAQ futures

    18,804.25
    -136.25 (-0.72%)
     
  • VOLATILITY

    14.11
    +1.19 (+9.22%)
     
  • FTSE

    8,229.66
    -24.52 (-0.30%)
     
  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     
  • CAD/EUR

    0.6744
    -0.0008 (-0.12%)
     

STAAR Surgical First Quarter 2024 Earnings: Beats Expectations

STAAR Surgical (NASDAQ:STAA) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$77.4m (up 5.2% from 1Q 2023).

  • Net loss: US$3.34m (down by 223% from US$2.71m profit in 1Q 2023).

  • US$0.068 loss per share (down from US$0.056 profit in 1Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

STAAR Surgical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 31%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

ADVERTISEMENT

Performance of the American Medical Equipment industry.

The company's shares are down 8.2% from a week ago.

Risk Analysis

Be aware that STAAR Surgical is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.